

May 13, 2026
JCR Pharmaceuticals Co., Ltd.

Notice Concerning Partial Corrections to the Annual Securities Report for Past Fiscal Years and the Consolidated Financial Results for the Nine Months Ended December 31, 2025 (FY2025) and Other Relevant Documents

Hyogo, Japan – May 13, 2026 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”) announced today that it has issued partial corrections to its previously disclosed consolidated financial results and related materials, as described below. JCR also plans to submit amendment reports for the relevant securities reports and other statutory disclosure documents to the Kanto Local Finance Bureau around late June 2026, following completion of the required audit procedures and other necessary procedures by its independent auditor.

1. Background and Reason for the Corrections

In the fiscal year ended March 31, 2025, JCR expensed inventories of manufacturing-related materials, investigational drugs, and other items that were no longer expected to be used. However, certain items included in this expense recognition had already been expensed. In addition, construction in progress had been recorded twice at certain subsidiaries.

As a result, JCR has made the necessary corrections in accordance with Accounting Standards Board of Japan Statement No. 24, “Accounting Standard for Disclosure of Accounting Policies, Accounting Changes and Corrections of Errors.” JCR has therefore corrected and released the previously disclosed annual and quarterly consolidated financial results listed below.

2. Corrections to Financial Results Summaries Released Today

Annual Financial Results

- Financial Summary Consolidated Financial Results for the Year ended March 31, 2025 (FY2024) (Japanese standard)

Quarterly Financial Results

- Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2025 (FY2025) (Japanese standard)
- Financial Summary Consolidated Financial Results for the Six Months ended September 30, 2025 (FY2025) (Japanese standard)
- Financial Summary Consolidated Financial Results for the Nine Months ended December 31, 2025 (FY2025) (Japanese standard)

3. Amendment Reports Scheduled for Submission in Late June 2026 (Japanese Only)

Securities Report

- 50th Fiscal Year (from April 1, 2024 to March 31, 2025)

Semiannual Report

- 51st Fiscal Year (from April 1, 2025 to September 30, 2026)

4. Impact of the Corrections on Results for the Current and Prior Fiscal Year

Consolidated Financial Statements

(Unit: Millions of yen)

Period	Item	Before Correction	After Correction	Impact	Change (%)
Full Year Ended March 31, 2025 (FY2024)	Net Sales	33,072	33,072	—	—
	Operating profit	(6,650)	(6,219)	430	—
	Ordinary profit	(7,477)	(7,046)	430	—
	Profit attributable to owners of parent	(4,759)	(4,460)	299	—
	Total assets	104,855	104,849	(6)	(0.0)%
	Net assets	47,435	47,734	299	0.6%
Three Months ended June 30, 2025 (FY2025)	Net Sales	8,569	8,569	—	—
	Operating profit	(606)	(606)	—	—
	Ordinary profit	(749)	(749)	—	—
	Profit attributable to owners of parent	(546)	(546)	—	—
	Total assets	107,337	107,336	(0)	(0.0)%
	Net assets	46,614	46,913	299	0.6%
Six Months ended September 30, 2025 (FY2025)	Net Sales	21,362	21,362	—	—
	Operating profit	2,379	2,429	50	2.1%
	Ordinary profit	2,362	2,413	50	2.1%
	Profit attributable to owners of parent	1,710	1,746	35	2.1%
	Total assets	109,055	108,956	(98)	(0.1)%
	Net assets	48,517	48,852	334	0.7%
Nine Months ended December 31, 2025 (FY2025)	Net Sales	30,353	30,353	—	—
	Operating profit	427	477	50	11.9%
	Ordinary profit	711	761	50	7.1%
	Profit attributable to owners of parent	1,744	1,779	35	2.0%
	Total assets	113,306	113,195	(110)	(0.1)%
	Net assets	46,750	47,084	334	0.7%

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values –

Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>

Contact:

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###